Anne Angelillo-Scherrer

Title: **Anne Angelillo-Scherrer: Innovator in Gene Therapy**

Introduction

Anne Angelillo-Scherrer, a talented inventor based in Fribourg, Switzerland, has made significant contributions to the field of gene therapy. With a total of two patents to her name, she focuses on innovative approaches for treating bleeding disorders, particularly hemophilia. Her work stands out for its potential therapeutic applications and advances in medical science.

Latest Patents

Anne's most recent patents include groundbreaking inventions aimed at inhibiting PROS1 gene expression. The first patent, titled "Nucleic acids for inhibiting expression of PROS1 in a cell," outlines nucleic acid products designed to interfere with the PROS1 gene, which has implications for the treatment of bleeding disorders. Her second patent, "Use of specific siRNA against protein S for the treatment of hemophilia," provides a method to administer siRNA targeting protein S as a treatment for hemophilia. This innovation highlights a promising avenue for patients in need of effective therapies.

Career Highlights

Throughout her career, Anne has been associated with prestigious institutions, including Universität Bern and Silence Therapeutics GmbH. Her experiences in these organizations have contributed to her expertise and growth as an inventor. She continually seeks to bridge the gap between research and practical treatment options in the medical field.

Collaborations

Anne has had the opportunity to work alongside esteemed colleagues, including Raja Prince El Adnani and Ute Schaeper. These collaborations have enriched her work and fostered a collaborative environment in which innovative ideas and research can thrive.

Conclusion

Anne Angelillo-Scherrer exemplifies the spirit of innovation and dedication in the scientific community. With her impactful patents and collaborations, she is making strides in the fight against bleeding disorders and demonstrating the importance of gene therapy research.